Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EQRX

EQRx (EQRX) Stock Price, News & Analysis

EQRx logo

About EQRx Stock (NASDAQ:EQRX)

Advanced Chart

Key Stats

Today's Range
$2.34
$2.34
50-Day Range
$2.04
$2.47
52-Week Range
$1.58
$5.55
Volume
N/A
Average Volume
3.30 million shs
Market Capitalization
$1.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.

Receive EQRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter.

EQRX Stock News Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
AUROW Aurora Innovation, Inc. WT EXP 110326
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
See More Headlines

EQRX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that EQRx investors own include Meta Platforms (META), NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Exxon Mobil (XOM), CrowdStrike (CRWD) and GE Aerospace (GE).

Company Calendar

Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EQRX
Fax
N/A
Employees
362
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$169.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.40 per share
Price / Book
0.98

Miscellaneous

Free Float
398,218,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
0.48
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:EQRX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners